- Home
- NDLS vs CING Comparison
NDLS vs CING Comparison
Compare NDLS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- CING
- Stock Information
- Founded
- NDLS 1995
- CING 2012
- Country
- NDLS United States
- CING United States
- Employees
- NDLS N/A
- CING N/A
- Industry
- NDLS Restaurants
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- CING Health Care
- Exchange
- NDLS Nasdaq
- CING Nasdaq
- Market Cap
- NDLS 32.9M
- CING 26.7M
- IPO Year
- NDLS 2013
- CING 2021
- Fundamental
- Price
- NDLS $0.91
- CING $4.17
- Analyst Decision
- NDLS Strong Buy
- CING Strong Buy
- Analyst Count
- NDLS 2
- CING 4
- Target Price
- NDLS $3.00
- CING $30.67
- AVG Volume (30 Days)
- NDLS 125.0K
- CING 140.6K
- Earning Date
- NDLS 08-06-2025
- CING 08-19-2025
- Dividend Yield
- NDLS N/A
- CING N/A
- EPS Growth
- NDLS N/A
- CING N/A
- EPS
- NDLS N/A
- CING N/A
- Revenue
- NDLS $495,670,000.00
- CING N/A
- Revenue This Year
- NDLS $5.37
- CING N/A
- Revenue Next Year
- NDLS $0.68
- CING N/A
- P/E Ratio
- NDLS N/A
- CING N/A
- Revenue Growth
- NDLS N/A
- CING N/A
- 52 Week Low
- NDLS $0.55
- CING $1.80
- 52 Week High
- NDLS $1.80
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- NDLS 52.85
- CING 37.87
- Support Level
- NDLS $0.83
- CING $4.80
- Resistance Level
- NDLS $0.95
- CING $5.74
- Average True Range (ATR)
- NDLS 0.10
- CING 0.43
- MACD
- NDLS -0.01
- CING -0.16
- Stochastic Oscillator
- NDLS 26.67
- CING 8.75
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.